Pandemic and All-Hazards Preparedness and Response Act

H.R. 1, the One Big, Beautiful Bill Act H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Seniors timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs S. 998, Medical Supply Chain Resiliency Act S 106 / HR 539 - Chiropractic Medicare Coverage Modernization Act PAMA reform HR 2483, Support for Patients and Communities Reauth Act HR 2484, Seniors access to Critical medications act Reducing Hereditary Cancer Act S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S 1830 - the Right to Treat Act S 1811 - Prohibits Graduate medical schools from receiving Federal assistance if DEI policies are in place S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine S 2066, Medicare transaction Fraud prevention act LCD legislation S 1866 - National Breast and Cervical Cancer Early Detection Program S 1882 - to expand research and training on reproductive health conditions HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act

Client expense: $149,447 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues pertaining to vector-borne disease. S.2580, SMASH 2.0 Act, Issues pertaining to re-introduction, expanded and clarified use of funds for vector management. Kay Hagan Tick Act, Issues pertaining to re-authorization, continuation and expansion of support for response to vector born disease. H.R. 4420, S. 2333, Preparedness and Response Reauthorization Act, Pandemic and All-Hazards Preparedness and Response Act, Issues pertaining to the reauthorization of the Pandemic and All-Hazards Preparedness Act, including provisions on vector management. One Health Security Act, All provisions, including issues pertaining to vector-borne disease and scientific research.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act

Client expense: $217,588 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2940 and S. 1355 (PASTEUR Act of 2023), all provisions H.R. 4420 (Preparedness and Response Reauthorization Act), all provisions H.R. 4421 (Preparing for all Hazards and Pathogens Reauthorization Act), all provisions S. 2333 (Pandemic and All-Hazards Preparedness and Response Act), all provisions Note: Elizabeth Horner, a lobbyist for the listed client, did not lobby, and did not make any communication to, appearance before, or lobbying contact with, the Senate, any Senator or any officer or employee of the Senate, on behalf of the listed client.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitored issues related to pharmaceutical prices. Issues related to dialysis. Issues regarding the pharmaceutical supply chain. Issues concerning drug shortages. Monitored issues concerning sterilization of medical devices. S. 2333, Pandemic and All-Hazards Preparedness and Response Act (PAHPA). H.R. 4421, the Preparing for All-Hazards and Pathogen Reauthorization Act (PAHPA). Monitored AI issues. Monitored cybersecurity issues. Issues concerning Hurricane Helene. H.R. 10545, American Relief Act, 2025 and H.R. 10445, Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025 and issues related to PAHPA and access to IV Solutions.

Client expense: Not reported · Firm income: $110,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu (generally, no specific bill)

Client expense: $247,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);HIV Epidemic Loan Repayment Program (HELP) Act(H.R. 2295) Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), PHE Outbreak Activation Act (not-yet introduced), PREVENT Pandemics Act, Preparing for All Hazards and Pathogens Reauthorization Act (HR 4421), Pandemics and All-Hazards Preparedness and Response Act (S.2333), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill)

Client expense: $255,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals including Strategic National Stockpile appropriations and reauthorization of the Pandemic and All-Hazards Preparedness Act, S.2333, Pandemic and All-Hazards Preparedness and Response Act, H.R.4421, Preparing for All Hazards and Pathogens Reauthorization Act; S.2624/HR 5894, Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored S. 2333, Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Monitored issues related to drug pricing. H.R. 10445, Furthering Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025, as it relates to pharmacy benefit management reforms and SUPPORT Act. H.R. 10545, The American Relief Act of 2025.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitored S. 2333, Pandemic and All-Hazards Preparedness and Response Act regarding PAHPA reauthorization. Monitored H.R. 4421, the Preparing for All-Hazards and Pathogen Reauthorization Act. H.R. 10445, Furthering Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025. S. 2840, Bipartisan Primary Care and Health Workforce Act, as it relates to hospitals and the healthcare workforce. Monitored issues related to the World Trade Center Health Program. Monitored issues regarding ARPA-H. Issues involving drug shortages. Issues regarding NIH reform. Issues related to hurricane response.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 456: Fairness in Orphan Drug Exclusivity Act H.R. 766: Dr. Michael C. Burgess Preventive Health Savings Act H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1613: Drug Price Transparency in Medicaid Act of 2023 H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program H.R. 2679: Pharmacy Benefits Manager Accountability Act H.R. 2707: MADE in America Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3433: Give Kids a Chance Act of 2024 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3839: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act H.R. 4818: Treat and Reduce Obesity Act of 2023 H.R. 4895: Lowering Drug Costs for American Families Act - Provisions related to drug pricing H.R. 4988: Modern Authentication of Pharmaceuticals Act of 2023 H.R. 5376: Share the Savings with Seniors Act  H.R. 5378: Lower Costs, More Transparency Act H.R. 5391: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 5539: ORPHAN Cures Act H.R. 6283: Delinking Revenue from Unfair Gouging or DRUG Act H.R. 6664: Innovation in Pediatric Drugs Act of 2023 H.R. 7024 Tax Relief for American Families and Workers Act of 2024 H.R. 7174: Ensuring Pathways to Innovative Cures (EPIC) Act: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7248: FDA Modernization Act 3.0 H.R. 7623: Telehealth Modernization Act of 2024 H.R. 7635: The 340B PATIENTS Act of 2024 H.R. 8574: 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act H.R. 9096: Pharmacists Fight Back Act S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1130: Health Care PRICE Transparency Act S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 1589: Safeguarding Patients and Taxpayers Act S. 1967: PBM Act S. 2305: Biosimilar Red Tape Elimination Act S. 2333: Pandemic and All-Hazards Preparedness and Response Act S. 2474: Share the Savings with Seniors Act S. 2477: Equitable Community Access to Pharmacist Services Act S. 2973: Modernizing and Ensuring PBM Accountability Act (MEPA) S. 3393: SUPPORT for Patients and Communities Reauthorization Act S. 3430: Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S. 5021: 340B PATIENTS Act of 2024 S. 5040: Protecting Patients from Deceptive Drugs Online Act S. 5459: Biosimilars Access and Affordability Act BioCompete Act (draft) Executive Order of February 28, 2024, Preventing Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) User fee policy issues Inflation Reduction Act of 2022 (P.L. 117-169) IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues Clinical trial diversity policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues Vaccine provisions of the Inflation Reduction Act Policy issues related to vaccines

Client expense: $920,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

H.R. 2940 and S. 1355 (PASTEUR Act of 2023), all provisions H.R. 4420 (Preparedness and Response Reauthorization Act), all provisions H.R. 4421 (Preparing for all Hazards and Pathogens Reauthorization Act), all provisions S. 2333 (Pandemic and All-Hazards Preparedness and Response Act), all provisions

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R. 7623: Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.

Client expense: $560,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 456: Fairness in Orphan Drug Exclusivity Act H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1613: Drug Price Transparency in Medicaid Act of 2023 H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program H.R. 2679: Pharmacy Benefits Manager Accountability Act H.R. 2707: MADE in America Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3433: Give Kids a Chance Act of 2024 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3839: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act H.R. 4818: Treat and Reduce Obesity Act of 2023 H.R. 4895: Lowering Drug Costs for American Families Act - Provisions related to drug pricing H.R. 4988: Modern Authentication of Pharmaceuticals Act of 2023 H.R. 5376: Share the Savings with Seniors Act  H.R. 5378: Lower Costs, More Transparency Act H.R. 5391: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 5539: ORPHAN Cures Act H.R. 6283: Delinking Revenue from Unfair Gouging or DRUG Act H.R. 6664: Innovation in Pediatric Drugs Act of 2023 H.R. 7174: Ensuring Pathways to Innovative Cures (EPIC) Act: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7248: FDA Modernization Act 3.0 H.R. 7623: Telehealth Modernization Act of 2024 H.R. 7635: The 340B PATIENTS Act of 2024 H.R. 8574: 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act H.R. 9096: Pharmacists Fight Back Act S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1130: Health Care PRICE Transparency Act S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1497: Emergency Access to Insulin Act of 2023 S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 1589: Safeguarding Patients and Taxpayers Act S. 1967: PBM Act S. 2305: Biosimilar Red Tape Elimination Act S. 2333: Pandemic and All-Hazards Preparedness and Response Act S. 2474: Share the Savings with Seniors Act S. 2973: Modernizing and Ensuring PBM Accountability Act S. 3393: SUPPORT for Patients and Communities Reauthorization Act S. 3430: Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S. 5021: 340B PATIENTS Act of 2024 S. 5040: Protecting Patients from Deceptive Drugs Online Act S. 5459: Biosimilars Access and Affordability Act BioCompete Act (draft) Executive Order of February 28, 2024, Preventing Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) User fee policy issues Inflation Reduction Act of 2022 (P.L. 117-169) IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues Clinical trial diversity policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues

Client expense: $7,560,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- S.2333 - Pandemic and All-Hazards Preparedness and Response Act, provisions related to health care provider workforce - S.1176 & H.R.2663 - Workplace Violence Prevention for Health Care and Social Service Workers Act - S.4928 - Beryllium Testing Fairness Act - H.R.4897 & S.2501 - Asuncion Valdivia Heat Illness and Fatality Prevention Act - H.R.5420 & S.2948 - WORK (Workplace Overdose Reversal Kits) to Save Lives Act - H.R. 766 & S.114 - Dr. Michael C. Burgess Preventive Health Savings Act - Authorization legislation to establish a program to provide federal support to graduate medical education programs in occupational and environmental medicine. - Medicare GME system reforms to accommodate support for additional medical specialty residency funding support. - Support of Congressional oversight on issues related to occupational respirable crystalline silica exposures. - Support of Congressional oversight on issues related to occupational lead exposures. - Support of Congressional oversight on issues related to on-site workplace clinic illness and injury management.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Occupational Safety & Health Administration (OSHA), SENATE

Issues related to lung disease treatment, prevention and research; Issues related to public health; Issues related asthma, COPD, influenza, lung cancer, pneumonia, pulmonary fibrosis, tuberculosis and other lung diseases; Issues related to tobacco cessation; Issues related to the Affordable Care Act; Issues related to the Childrens Health Insurance Program; Issues related to Medicaid; Issues related to ERISA; Issues related to COVID-19 Response; Issues related to vaccines; Issues related to infrastructure; Issues related to supplemental oxygen; Issues related to the implementation of the No Surprises Act; Issues related to Medicare sequestration; Issues related to Cancer Moonshot; Issues related to short-term limited duration plans; Issues related to Healthy Future Taskforce; Issues related to regulatory reform; Issues relating to FY25 appropriations; Issues relating to the Presidents FY26 budget; HR 277 REINS Act; S 184 REINS Act; HR 1075 Medicaid Work Requirements Act; S. 1063 A bill to amend title XIX of the Social Security Act to implement a minimum work requirement for able-bodied adults enrolled in State Medicaid programs; HR 1551 Jobs and Opportunities for Medicaid Act; H.R. 2583 Increasing Access to Quality Cardiac Rehabilitation Care Act of 2023; H.R. 1114 Long COVID RECOVERY NOW Act; H.R. 1692 Health Care Affordability Act of 2023; HR 3073 Community Mental Wellness and Resilience Act; S 1452 Community Mental Wellness and Resilience Act; HR 2811 Limit Save Grow Act; HR 442 Regulatory Accountability Act; S 1615 Regulatory Accountability Act;; HR 288 Separation of Powers Restoration Act of 2023; S 1411, Prove It Act of 2023; S 1995 Public Health Infrastructure Saves Lives Act; HR 824 Telehealth Benefit Expansion for Workers Act of 2023; HR 4286 Increasing Access to Lung Cancer Screening Act; HR 2813 The Self-Insurance Protec􀆟on Act; HR 3799 CHOICE Arrangement Act; HR 2868 Association Health Plans Act; S 2213 Comprehensive Cancer Survivorship Act; HR 4363 Comprehensive Cancer Survivorship Act; S. 2016 CONNECT for Health Act of 2023; HR 4189 CONNECT for Health Act of 2023;; HR 5749 Family Asthma Act; HR 4286 Increasing Access to Lung Cancer Screening Act; HR 890 The Guidance Out of Darkness Act; S 791 The Guidance Out of Darkness Act; S 2245 Women and Lung Cancer Research and Preventive Services Act; HR 4534 Women and Lung Cancer Research and Preventive Services Act; S 2333 Pandemic and All Hazards Preparedness and Response Act; HR 4420 Pandemic and All-Hazards Preparedness and Response Act; S 1489 National Task Force on the COVID-19 Pandemic Act;; HR 6302 Health Share Transparency Act; HR 357 Ensuring Accountability in Agency Rulemaking;; S3821 Supplemental Oxygen Access Reform (SOAR) Act; HR7829 Supplemental Oxygen Access Reform (SOAR) Act; HR 485 Protecting Health Care for All Patients Act of 2023; HR 7867 Renewing Efficiency in Government by Budgeting Act; HR 115 Midnight Rules Relief Act, HR 1602, Health Care Affordability Act of 2023; S. 8 Improving Health Insurance Affordability Act of 2023; HR 9029 Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, 2025; H.R. 8774 Department of Defense Appropriations Act 2025; S. 4942 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; S 4921 Department of Defense Appropriations Act 2025; HR 890 Guidance out of Regulatory Darkness Act; H.R. 9774, Health Care Affordability Act of 2024; S. 5194 Health Care Affordability Act of 2024; S. 652 Safe Step Act; HR 2630 Safe Step Act; HR 10515, American Relief Act, 2025; HR 10545, American Relief Act, 2025

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office

Issues related to the health impacts of air pollution and climate change; Issues related to air pollution from stationary and mobile sources; Issues related to the Clean Air Act; Issues related to permitting and regulatory reforms; Issues related to infrastructure; Issues relating to FY25 appropriations; Issues relating to the Presidents FY26 budget; Issues related to implementation of the Inflation Reduction Act; Issues related to appliance efficiency; issues related to prescribed burning; HR 277 REINS Act; S 184 REINS Act; H.R. 165 New Source Review Permitting Improvement Act; S. 67 Fair and Transparent Gas Prices Act; S. 240 Gas Stove Protection and Freedom Act; HR 1615 Gas Stove Protection and Freedom Act; HR 1 Lower Energy Costs Act; HR 1435 to prevent the elimination of the sale of combustion vehicles; S 615 Cabin Air Safety Act; HR 1293 Cabin Air Safety Act; HR 1705 A. Donald McEachin Environmental Justice for All Act; S 919 A. Donald McEachin Environmental Justice for All Act; HR 1023 To repeal section 134 of the Clean Air Act, relating to the greenhouse gas reduction fund; HR 1131 To require the Administrator of the EPA to authorize the use of flexible air permitting with respect to certain critical energy resource facilities, and for other purposes; HR 1140 To authorize the Administrator of the EPA to waive application of certain requirements with respect to processing and refining a critical energy resource at a critical energy resource facility, and for other purposes; HR 1141 Natural Gas Tax Repeal Act;; S 1229 Green New Deal for Health; S. 1449RESTART ACT; S. 1399 Building American Energy Security Act of 2023; HR 1640Save Our Gas Stoves Act; S 1772Comprehensive National Mercury Monitoring Act; Promoting Efficient and Engaged Reviews (PEER) Act; S. 1930 Community Facilities Program for Rural Clean School Bus Infrastructure and Workforce Act; S 2179 Clean Cooking Support Act; H.R 4455 Community Facilities Program for Rural Clean School Buses Infrastructure Act; HR 3073 Community Mental Wellness and Resilience Act; S 1452 Community Mental Wellness and Resilience Act; HR 2811Limit Save Grow Act; HR 442 Regulatory Accountability Act; S 1615 Regulatory Accountability Act;; S. 2125 National Ambient Air Quality Standards Implementation Act of 2023; S. 2195 A bill to amend the Energy Policy Act of 2005 to reauthorize the diesel emissions reduction program; HR 288 Separation of Powers Restoration Act of 2023; HR 4211 Technology Assessment for Air Quality Management Act of 2023; S 2045 Technology Assessment for Air Quality Management Act of 2023;; HJ Res 69 Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Federal 'Good Neighbor Plan' for the 2015 Ozone National Ambient Air Quality Standards"; SJ Res 31 Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Federal 'Good Neighbor Plan' for the 2015 Ozone National Ambient Air Quality Standards"; HR 4077 Cleaner Air Spaces Act of 2023; HR 5533 Healthy At Home Act; S 2834 Healthy At Home Act; HR 890 The Guidance Out of Darkness Act; S 791 The Guidance Out of Darkness Act; HR 1435 Preserving Choice in Vehicle Purchases Act; HR 4468 The Choice in Automobile Retail Sales Act of 2023; S 2333 Pandemic and All Hazards Preparedness and Response Act; HR 4420 Pandemic and All Hazards Preparedness and Response Act;; SJ Res 11 a joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Control of Air Pollution From New Motor Vehicles: Heavy-Duty Engine and Vehicle Standards"; S 2383 Smoke and Heat Ready Communities Act; HR 4733 Smoke and Heat Ready Communities Act;; HR 6013 Promoting Reduction of Emissions through Landscaping Equipment Act; S 3371 Fostering Overseas Rule of Law and Environmentally Sound Trade (FOREST) Act; HR 357 Ensuring Accountability in Agency Rulemaking; HR 6621 Smoke Mitigation Occupational and Key Enhancements Act; S 3094 Choice in Automobile Retail Sales Act of 2023; ; HR 6192 Hands Off Our Home Appliances Act; HR 6421 Affordable HOMES Act;;; S 1863 PROVE It Act of 2024; S 2781 Good Samaritan Remediation of Abandoned Hardrock Mines Act; HR Res 987 Denouncing the harmful, anti-American energy policies of the Biden administration, and for other purposes; SJ Res 58 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Furnaces"; HJ Res 11 Disapproving the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Furnaces; HR 7193 Wildfire Air Quality Act; HR 7039 Stronger Communities Through Better Transit Act; HR7650 Air Quality Standards Implementation Act; S 3826 Modernizing Clean Air Permitting Act; HR Res 117Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Reconsideration of the National Ambient Air Quality Standards for Particulate Matter"; HR 7673 Liberty in Laundry Act; HR 7645 Clothes Dryer Reliability Act; HR 7700 Stop the Unaffordable Dishwasher Standards Act; HR 7637 Refrigerator Freedom Act; HR 7626 Affordable Air Conditioning Act; HR 7526 DC Consumer Vehicle Choice Protection Act; HR 1023To repeal section 134 of the Clean Air Act, relating to the greenhouse gas reduction fund.; S 4072 A bill to prohibit the use of funds to implement, administer, or enforce certain rules of the Environmental Protection Agency; SJ Res 65A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Reconsideration of the National Ambient Air Quality Standards for Particulate Matter"; HR 7867 Renewing Efficiency in Government by Budgeting Act; S 4153 A bill to require the Environmental Protection Agency to assess the lifecycle greenhouse gas emissions associated with the forest biomass combustion for electricity when developing relevant rules and regulations and to carry out a study on the impacts of the forest biomass industry, and for other purposes; H.J. Res 128 Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Standards of Performance for New, Reconstructed, and Modified Sources and Emissions Guidelines for Existing Sources: Oil and Natural Gas Sector Climate Review"; SJ Res 71A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Standards of Performance for New, Reconstructed, and Modified Sources and Emissions Guidelines for Existing Sources: Oil and Natural Gas Sector Climate Review".; HJ Res 136 Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Multi-pollutant Emissions Standards for Model Years 2027 and Later Light-Duty and Medium-Duty Vehicles.; SJ Res 75 Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Multi-pollutant Emissions Standards for Model Years 2027 and Later Light-Duty and Medium-Duty Vehicles.; SJ Res 74 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Greenhouse Gas Emissions Standards for Heavy-Duty Vehicles-Phase 3"; HJ Res 133 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Greenhouse Gas Emissions Standards for Heavy-Duty Vehicles-Phase 3"; SJ Res 88 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "National Emission Standards for Hazardous Air Pollutants: Coal- and Oil-Fired Electric Utility Steam Generating Units Review of the Residual Risk and Technology Review"; HJ Res 150 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "National Emission Standards for Hazardous Air Pollutants: Coal- and Oil-Fired Electric Utility Steam Generating Units Review of the Residual Risk and Technology Review"; SJ Res 87 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of the Treasury relating to "Clean Vehicle Credits Under Sections 25E and 30D; Transfer of Credits; Critical Minerals and Battery Components; Foreign Entities of Concern; HJ Res 148 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of the Treasury relating to "Clean Vehicle Credits Under Sections 25E and 30D; Transfer of Credits; Critical Minerals and Battery Components; Foreign Entities of Concern; S. 4405 A bill to amend the Clean Air Act to repeal the natural gas tax; S. 4424 National Prescribed Fire Act; H.R. 8557 National Prescribed Fire Act; SJ Res 92 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "New Source Performance Standards for Greenhouse Gas Emissions From New, Modified, and Reconstructed Fossil Fuel-Fired Electric Generating Units; Emission Guidelines for Greenhouse Gas Emissions From Existing Fossil Fuel-Fired Electric Generating Units; and Repeal of the Affordable Clean Energy Rule"; HJ Res 163 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "New Source Performance Standards for Greenhouse Gas Emissions From New, Modified, and Reconstructed Fossil Fuel-Fired Electric Generating Units; Emission Guidelines for Greenhouse Gas Emissions From Existing Fossil Fuel-Fired Electric Generating Units; and Repeal of the Affordable Clean Energy Rule"; HR 115 Midnight Rules Relief Act; HR 1507 Stop Corporate Capture Act; HR 8998 Department of the Interior, Environment and Related Agencies Act, 2025; HR 9028 Transportation Housing and Urban Development and Related Agencies Appropriations Act, 2025; HR 9029 Departments of Labor, Health and Human Services, and Education, and related agencies Act; S. 4942 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; S 4802 Department of the Interior, Environment and Related Agencies Act, 2025; S 4796 Transportation Housing and Urban Development and Related Agencies Appropriations Act, 2025; HR 8656 Modernizing Wildfire Safety and Prevention Act; HR 9131 To authorize a national program to reduce the threat to human health posed by exposure to indoor air contaminants, and for other purposes; S 4753 Energy Permitting Reform Act of 2024; S.J. Res 104 Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the National Highway Traffic Safety Administration relating to Corporate Average Fuel Economy Standards for Passenger Cars and Light Trucks for Model Years 2027 and Beyond and Fuel Efficiency Standards for Heavy-Duty Pickup Trucks and Vans for Model Years 2030 and Beyond; HR 9230 The Climate Pollution Standard and Community Investment Act; HR8784 Full Responsibility and Expedited Enforcement (FREE) Act; S 5308 Stop CARB Act; HR 9574 Stop CARB Act; HR 9676 Accelerating a Circular Economy for Plastics and Recycling Innovation Act; HR 8790 Fix Our Forests Act; HR 7980 End Chinese Dominance of Electric Vehicles Act; HR 890 Guidance out of Regulatory Darkness Act; HR 9894 Cool Roof Rebate Act of 2024; S 5318 Healthy Home at Base Act; HR 5533 Healthy Home at Base Act; HR 9982 Childrens Health Protection Act; HJ Res 228 Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Waste Emissions Charge for Petroleum and Natural Gas Systems: Procedures for Facilitating Compliance, Including Netting and Exemptions"; SJ Res 122 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Waste Emissions Charge for Petroleum and Natural Gas Systems: Procedures for Facilitating Compliance, Including Netting and Exemptions". HR 10515, American Relief Act, 2025; HR 10545, American Relief Act, 2025

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Internal Revenue Service (IRS), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), White House Office

PAHPA reauthorization, including S.2333 - the Pandemic and All-Hazards Preparedness and Response Act and H.R.4421 - Preparing for All Hazards and Pathogens Reauthorization Act; Pharmaceutical supply chain issues; H.R.6992/S.2364 - MAPS Act; H.R.3008 - Drug Shortage Prevention and Mitigation Act; Issues related to drug shortages.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.2333 - Pandemic and All-Hazards Preparedness and Response Act (provisions related to the Vaccine Injury Compensation Program and Vaccine Provisions).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 2333, Pandemic and All-Hazards Preparedness and Response Act. H.R. 4421, the Preparing for All-Hazards and Pathogen Reauthorization Act. Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2025. Opioid and heroin addiction legislation, naloxone access and awareness.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

S. 2840, Bipartisan Primary Care and Health Workforce Act, as it relates to hospitals and the health care workforce. Issues related to behavioral health. Issues related to hospital reimbursement. Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to hospitals. Monitored S. 2333, Pandemic and All-Hazards Preparedness and Response Act. Monitored H.R. 4421, the Preparing for All-Hazards and Pathogen Reauthorization Act. Monitored SUPPORT Act reauthorization. Issues related to hurricane response. H.R. 10545, American Relief Act of 2025 and issues related to hospitals. H.R. 10445, Furthering Continuing Appropriations and Disaster Relief Supplemental Appropriations Act of 2025 and issues related to hospitals.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

SUPPORT for Patients and Communities Reauthorization Act (HR 4531 / S 2433, S 3106, S 3393); HEAL Act (HR 4007 / S 2809); PAHPA Act (HR 4421 / S 2333); Reentry Act (HR 2400 / S 1165); Due Process Continuity of Care Act (HR 3074 / S 971); FY25 appropriations for Labor-HHS-Education, Military Construction & Veterans Affairs, and Commerce-Justice-Science; DEA rulemaking on telemedicine prescribing of controlled substances (RIN #1117-AB40); CMS Physician Fee Schedule CY25 Proposed Rule (RIN #0938-AV33);Continuing appropriations for FY25 (HR 9747, HR 10545)

Client expense: $230,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

S.652 - Safe Step Act (Murkowski/Hassan), support passage H.R. 830 - HELP Copays Act, support passage S.935- Fair Accountability and Innovative Research Drug Pricing Act of 2023, support passage H.R. 485, Protecting Health Care For All Patients Act, oppose passage as currently written S.127, the Pharmacy Benefit Manager Transparency Act, support passage Urged HELP and House Energy and Commerce Committee to hold roundtables and advance proposals that address workforce issues within the healthcare community. S. 2333 - Pandemic and All-Hazards Preparedness and Response Act, support passage H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023, oppose passage H.R. 4421, Preparing for All Hazards and Pathogens Reauthorization Act, monitor legislation H.R. 4420, Preparedness and Response Reauthorization Act, monitor legislation Committee Draft -The Primary Care and Health Workforce Expansion Act, support passage S. 1339, the Pharmacy Benefit Manager Reform Act, support passage S.127, the PBM Transparency Act of 2023, support passage S.113, The Prescription Pricing for the People Act of 2023, support passage S.2052, Protect Patient Access to Pharmacies Act H.R. 1692, Health Care Affordability Act of 2023 H.R. 3561, the PATIENT Act of 2023, support passage H.R. 3284, Providers and Payers Compete Act, support passage H.R. 4507, Transparency in Coverage Act, support passage H.R. 4508, Hidden Fee Disclosure Act, support passage H.R. 2816, PBM Sunshine and Accountability Act, support passage S.79- Interagency Patent Coordination and Improvement Act of 2023, support passage S. 142- Preserve Access to Affordable Generics and Biosimilars Act, support passage S.148- Stop STALLING Act, support passage S.150- Affordable Prescriptions for Patients Act of 2023, support passage S.775-Increasing Transparency in Generic Drug Applications Act, monitoring S.1067-Ensuring Timely Access to Generics Act of 2023, support passage S. 2780 Medication Affordability and Patent Integrity Ac H.R. 4189, the CONNECT for Health Act, support passage H.R. 1843, the Telehealth Expansion Act, support passage H.R. 8018, the Alleviating Barriers for Caregivers Act, support passage S. 3109, the Alleviating Barriers for Caregivers Act, support passage H.R.6302, the Health Share Transparency Act of 2023 H.R.7623, the Telehealth Modernization Act of 2024

Client expense: $51,247 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

FY 2024 and 2025 Appropriations, including Regional Biocontainment Laboratories (RBLs), PAHPA reauthorization, and S.2333 - Pandemic and All-Hazards Preparedness and Response Act; H.R.4420 - Preparedness and Response Reauthorization Act; H.R.4421 - Preparing for All Hazards and Pathogens Reauthorization Act; S.4667 - Risky Research Review Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

PAHPA reauthorization (S. 2333 - Pandemic and All-Hazards Preparedness and Response Act; H.R. 4421 - the Preparing for All Hazards and Pathogens Reauthorization Act); Drug pricing issues; PBM reform (S. 2973 -Modernizing and Ensuring PBM Accountability Act and S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023); Rare Pediatric Disease Priority Review Voucher Program reauthorization (H.R. 7384/ S. 4583 - Creating Hope Reauthorization Act); National Vaccine Injury Compensation Program.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitored issues related to pharmaceutical prices. Issues related to dialysis. Issues regarding the pharmaceutical supply chain. Issues concerning drug shortages. Monitored issues concerning sterilization of medical devices. S. 2333, Pandemic and All-Hazards Preparedness and Response Act (PAHPA). H.R. 4421, the Preparing for All-Hazards and Pathogen Reauthorization Act (PAHPA). Monitored AI issues. Monitored cybersecurity issues. Issues concerning Hurricane Helene. H.R. 10545, American Relief Act, 2025 and H.R. 10445, Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025 and issues related to PAHPA and access to IV Solutions.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored S. 2333, Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Monitored issues related to drug pricing. H.R. 10445, Furthering Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025 and H.R. 10545, The American Relief Act of 2025, as they relate to pharmacy benefit management reforms and SUPPORT Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues involving workforce shortages. S. 2333, Pandemic and All-Hazards Preparedness and Response Act. Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to hospitals. Monitored issues related to behavioral health. Monitored SUPPORT Act Reauthorization. Issues related to workplace safety. S. 2840, Bipartisan Primary Care and Health Workforce Act, as it relates to hospitals and the healthcare workforce. Issues concerning hurricane response.

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Access to emergency medical supplies (including Personal Protective Equipment, COVID-19 tests, ventilators, and medications) during COVID-19 public health emergency Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) H.R. 4420, the Preparedness and Response Reauthorization Act H.R. 4421, the Preparing for All Hazards and Pathogens Reauthorization Act S.2333-Pandemic and All-Hazards Preparedness and Response Act

Client expense: $407,855 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. Issues related to Type 1 diabetes screening. H.R.10545, FY25 Continuing Appropriations.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development and distribution. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. S.3558 - Biosecure. H.R.10545, FY25 Continuing Appropriations.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. H.R.10545, FY25 Continuing Appropriations.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. H.R. 10545, FY25 Continuing Appropriations.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

National Defense Authorization Act for 2024, H.R. 2670 Pandemic and All-Hazards Preparedness and Response Act, S. 2333 Preparing for All Hazards and Pathogens Reauthorization Act, H.R. 4421 Further Consolidated Appropriations Act, 2024, H.R. 2882 Other issues related to the Strategic National Stockpile, Biodefense, Preparedness, Biomanufacturing

Client expense: $170,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), SENATE

National Defense Authorization Act for 2024, H.R. 2670 Pandemic and All-Hazards Preparedness and Response Act, S. 2333 Preparing for All Hazards and Pathogens Reauthorization Act, H.R. 4421 Further Consolidated Appropriations Act, 2024, H.R. 2882 Other issues related to the Strategic National Stockpile, Biodefense, Preparedness, Biomanufacturing

Client expense: $170,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), SENATE

Preparing for All Hazards and Pathogens Reauthorization Act, H.R. 4421 Pandemic and All-Hazards Preparedness and Response Act, S. 2333 Other Biomanufacturing & Preparedness Issues

Client expense: Not reported · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Preparing for All Hazards and Pathogens Reauthorization Act, H.R. 4421 Pandemic and All-Hazards Preparedness and Response Act, S. 2333 Other Biomanufacturing & Preparedness Issues

Client expense: Not reported · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to the medical-surgical supply chain including onshore and near-shore sourcing and legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421, S. 2333); see also Public Law No: 118-158.

Client expense: $210,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to pandemic preparedness and strategic stockpile readiness, including state strategic stockpiles demonstration included in the PREVENT Act. Pandemic and All-Hazards Preparedness Act reauthorization, H.R.4421, Preparing for All Hazards and Pathogens Reauthorization Act, S.2333, Pandemic and All-Hazards Preparedness and Response Act, and H.R.10445, Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.4421/S.2333 - Preparing for All-Hazards Preparedness Act (PAHPA) Reauthorization (issues related to ASPR authorization); S.2624 - Departments of Labor, Health and Human Services, and Education Appropriations Act, 2024 (issues related to Social Security Administration funding).

Client expense: $1,150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act

Client expense: $126,566 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and regulation related to health care delivery and health insurance coverage, mental health and substance use disorder care and coverage, the transition out of the COVID-19 pandemic and electronic health information/technology. H.R. 4527 Health DATA Act S. 3679, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 5378 the Lower Costs, More Transparency Act S.3548 - Health Care Prices Revealed and Information to Consumers Explained Transparency Act S.3430 - An original bill to amend titles XVIII and XIX of the Social Security Act to expand the mental health care workforce and services, reduce prescription drug costs, and extend certain expiring provisions under Medicare and Medicaid, and for other purposes. HR 3305 & S. 1606 Black Maternal Health Momnibus Act HR 4822 Health Care Price Transparency Act HR 3284 Providers and Payers COMPETE Act HR 2840 Bipartisan Primary Care and Health Workforce Act HR 4818 Treat and Reduce Obesity Act of 2023 S. 2333 Pandemic and All Hazards Preparedness and Response Act H.R. 4421 Preparing for All Hazards and Pathogens Reauthorization Act H.R. 3561, PATIENT Act of 2023 H.R. 3281, the Transparent PRICE Act H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information H.R. 2868 Association Health Plans Act H.R. 2813 Self-Insurance Protection Act H.R. 3799 CHOICE Arrangement Act H.R. 3432, Telemental Health Care Access Act H.R.824, Telehealth Benefit Expansion for Workers Act of 2023 H.R. 4189, S. 2016, CONNECT for Health Act S. 923, Better Mental Health Care for Americans Act H.R. 3120, Healthy Competition for Better Care Act H.R. 1843 Telehealth Expansion Act of 2023 S.954 - 118th Congress (2023-2024)A bill to provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025 H.R.10515 - American Relief Act, 2025 H.R.10545 - American Relief Act, 2025 H.R. 9774 & S. 5194 - Health Care Affordability Act of 2024 H.R. 3120 & S. 1451 - Healthy Competition for Better Care Act

Client expense: $220,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE